Table 1.
Patient baseline demographics and disease characteristics and background N[t]RTIs
| All patients N = 313 | Treatment-naïve patients N = 295 | |
|---|---|---|
| Male [n (%)] | 279 (89) | 266 (90) |
| Age, years [median (range)] | 35 (18–72) | 34 (18–72) |
| Race [n (%)] | ||
| White | 187 (60) | 176 (60) |
| Black or African Heritage | 108 (35) | 101 (34) |
| Asian | 4 (1) | 4 (1) |
| Other | 14 (4) | 14 (5) |
| Log10 VL (HIV-1 RNA copies/ml) [median (range)] | 4.8 (2.6–7.0) | 4.8 (2.6–7.0) |
| VL >100,000 HIV-1 RNA copies/ml [n (%)] | 131 (42) | 122 (41) |
| CD4+ cell count (cells/mm3) [median (range)] | 361 (5–1473) | 370 (6–1473) |
| ≤200 cells/mm3 [n (%)] | 59 (19) | 47 (16) |
| Asymptomatic HIV infection [n (%)] | 251 (80) | 241 (82) |
| Co-infection with HBV [n (%)] | 5 (2) | 5 (2) |
| Co-infection with HCV [n (%)] | 8 (3) | 7 (2) |
| eGFRCG, ml/min [median (range)] | 114 (67–321) | 115 (67–321) |
| Background N[t]RTIs [n (%)] | ||
| Emtricitabine/tenofovir | 301 (96) | 291 (99) |
| Emtricitabine/tenofovir plus zidovudine | 5 (2) | 0 |
| Abacavir plus tenofovir | 3 (1) | 2 (0.7) |
| Emtricitabine/tenofovir plus abacavir | 2 (0.6) | 1 (0.3) |
| Abacavir/lamivudine | 1 (0.3) | 1 (0.3) |
| Didanosine plus emtricitabine | 1 (0.3) | 0 |
N number of patients; n number of patients with observations; VL viral load; HBV hepatitis B virus; HCV hepatitis C virus; eGFR CG estimated glomerular filtration rate calculated using the Cockcroft-Gault method; N[t]RTIs nucleoside/tide reverse transcriptase inhibitors.